Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer
NCT03403777Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in germ cell tumor (GCT), sponsored by National Cancer Institute. Started Nov 2017; status: completed.
02
Drugs
avelumab
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT03403777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403777.